Oruka Therapeutics, Inc. (NASDAQ:ORKA) institutional investors have had a good week as stock gains 15%
Key Insights Institutions' substantial holdings in Oruka Therapeutics implies that they have significant influence ...
Oruka Therapeutics (ORKA) Gets a Buy from TD Cowen
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) today. The company’s shares closed ...
Promising Potential of Oruka Therapeutics’ ORKA-001 in Psoriasis Treatment
Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) and keeping the price target at ...
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Recommendation of “Buy” by Analysts
Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have earned a consensus rating of “Buy” from the eight ...
ETF Daily News17d
Oruka Therapeutics’ (ORKA) “Buy” Rating Reaffirmed at HC Wainwright
Oruka Therapeutics has a 1 year low of $18.20 and a 1 year high of $53.88. The company has a market capitalization of $654.15 million, a price-to-earnings ratio of -2.98 and a beta of 0.87.
WBOY22d
Paragon Therapeutics Appoints Susanna High as Chief Executive Officer
Spyre Therapeutics, Oruka Therapeutics, Jade Biosciences, and Crescent Biopharma. They have collectively raised approximately $2.7 billion and currently have four programs in clinical development.
Longview News-Journal23d
Transposon Therapeutics Strengthens and Expands Development Pipeline with the Acquisition of a Portfolio of Novel Nucleoside Analogs for Oncology
Transposon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a platform of novel nucleoside reverse transcriptase inhibitors for the treatment of neurodegenerative and ...